RBC lifts Medicines Co. to outperform

RBC Capital Markets analyst Jason Kantor upgraded The Medicines Co. to outperform, above average risk, from sector perform. Kantor also raised the price target to $30 from $24 in anticipation of increased market penetration of Angiomax following positive Acuity data and positive momentum following near-term news flow including publication of data in the New England Journal of Medicine.

Shares of the Parsippany, N.J.-based pharmaceutical company were up $1.11, or 4.73%, at $24.56. (Nasdaq: MDCO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.